President Donald Trump took a significant step in federal drug policy by signing an executive order on Thursday that could potentially reclassify marijuana to a less dangerous drug category, opening doors for expanded medical research. This move would shift marijuana from its current Schedule I classification, grouped with heroin and LSD, to a Schedule III substance, aligning it with substances like ketamine and certain anabolic steroids. While this reclassification would not legalize recreational marijuana nationwide, it could lead to changes in regulatory practices and ease the tax burden on the cannabis industry.
President Trump stated that he received overwhelming support for this decision, particularly from individuals advocating for the potential benefits to patients in need. In contrast, the Justice Department under former President Joe Biden had also proposed reclassifying marijuana to a Schedule III substance.
Despite some opposition within his own party, President Trump’s order aims to accelerate the reclassification process by the Drug Enforcement Administration (DEA), which was already under review when he assumed office. The timeline for this reclassification remains uncertain, but it could bring the U.S. closer to the legalization policies adopted by many states that permit adult recreational or medical marijuana use.
According to polling data from Gallup, public support for marijuana legalization has significantly increased over the years, from 36% in 2005 to 68% in the previous year. Trump’s executive order also includes provisions for expanded research and access to CBD, a hemp-derived product with debated benefits. Additionally, a new Medicare program would provide eligible older adults with access to legal hemp-derived CBD at no cost, upon doctor recommendation.
Despite resistance from over 20 Republican senators, including close allies of Trump, who urged him to maintain marijuana’s Schedule I status citing health and safety concerns, the executive order reflects a shift in federal drug policy under the current administration. Trump’s stance on decriminalization remains uncertain, but his focus on combatting other drugs like fentanyl has been a notable feature of his presidency, with recent executive orders declaring fentanyl a weapon of mass destruction.
Overall, President Trump’s executive order marks a significant development in federal drug policy, potentially paving the way for a reclassification of marijuana and facilitating increased research and access to related products for medical purposes.
